Renaissance Capital logo

HBT News

US IPO Week Ahead: Another biotech plans to take on the IPO market

KROS

Biotechs are back as another early stage biotech, Keros Therapeutics (KROS), plans to take on the IPO market in the week ahead, following last week's successful debut of Zentalis Pharmaceuticals (ZNTL). Keros Therapeutics, a Phase 1 biotech developing novel treatments for hematological and musculoskeletal disorders, plans to raise...read more

US IPO Weekly Recap: Two big biotechs and a bank squeeze through the IPO window

BNTX

Three IPOs raised a combined $426 million this week, all pricing below the midpoint and finishing below issue. On average they returned a disappointing -13.5%. Despite lopping $1 billion off of its proposed valuation, Germany-based BioNTech (BNTX) became the ...read more

Illinois bank HBT Financial prices IPO below the range at $16

HBT

HBT Financial, a family-owned bank with 64 branches in central and northeastern Illinois, raised $133 million by offering 8.3 million shares at $16, below the range of $17 to $19. HBT Financial plans to list on the Nasdaq under the symbol HBT. Keefe Bruyette Woods and J.P. Morgan acted as lead managers on the deal....read more

US IPO Week Ahead: 2 billion-dollar biotechs and a bank

BNTX

Two of the largest-ever biotech IPOs by market cap are scheduled for the week ahead. They are joined by an Illinois bank. The three deals plan to raise a combined $550 million. Germany-based BioNTech (BNTX) is targeting $251 million at a fully diluted market cap of $4.45 billion. That would make it the third-largest development-stage biotech ever to list in...read more